Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Abortion, Habitual D000026 5 associated lipids
Acidosis D000138 13 associated lipids
Adenocarcinoma D000230 166 associated lipids
Agranulocytosis D000380 7 associated lipids
Airway Obstruction D000402 13 associated lipids
Albuminuria D000419 18 associated lipids
Alcoholic Intoxication D000435 15 associated lipids
Anaphylaxis D000707 35 associated lipids
Anemia D000740 21 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Filep J and Rosenkranz B Mechanism of vasopressin-induced platelet aggregation. 1987 Thromb. Res. pmid:3105115
Ushiyama S et al. RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action. 1988 Thromb. Res. pmid:3175990
Rogasi PG et al. Radioimmunoassay of thromboxane B2 in plasma: methodological modifications. 1988 Thromb. Res. pmid:3175991
Kosaki G et al. The mechanism of the inhibitory effect of protease inhibitors on platelet aggregation and cellular synthesis of prostaglandins. I. The effect on the release of arachidonic acid from phospholipids. 1980 Dec 1-15 Thromb. Res. pmid:6785893
Butler KD et al. Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben. 1987 Thromb. Res. pmid:3109067
Watanabe T et al. Enhanced platelet sensitivity to prostacyclin in patients in an active stage of Takayasu arteritis. 2001 Thromb. Res. pmid:11672751
Addonizio VP et al. Inhibition of human platelet function by verapamil. 1982 Thromb. Res. pmid:7164035
Vargaftig BB et al. Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. 1982 Thromb. Res. pmid:7164036
Navran SS et al. Human platelet activation by bacterial phospholipase C is mediated by phosphatidylinositol hydrolysis but not generation of phosphatidic acid: inhibition by a selective inhibitor of phospholipase C. 1984 Thromb. Res. pmid:6372157
Rostagno C et al. In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation. Comparison with diltiazem, nifedipine and verapamil. 1991 Thromb. Res. pmid:1754998
Kankuri E et al. Effects of phenacetin and its metabolite p-phenetidine on COX-1 and COX-2 activities and expression in vitro. 2003 Thromb. Res. pmid:14592552
Di Minno G et al. Arachidonic acid induces human platelet-fibrin retraction: the role of platelet cyclic endoperoxides. 1982 Thromb. Res. pmid:6803385
Catella F and FitzGerald GA Paired analysis of urinary thromboxane B2 metabolites in humans. 1987 Thromb. Res. pmid:3686481
Suehiro A et al. The role of platelet hyperfunction in thrombus formation in hyperlipidemia. 1982 Thromb. Res. pmid:6803387
Riess H et al. Effects of BM 13.177, a new antiplatelet drug in patients with atherosclerotic disease. 1984 Thromb. Res. pmid:6237460
Weide I et al. Effects of cyclooxygenase inhibitors on ex vivo cysteinyl-leukotriene production by whole human blood allowed to clot spontaneously. Comparison to stimulated blood. 1992 Thromb. Res. pmid:1440511
Patrono C et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. 1980 Feb 1-15 Thromb. Res. pmid:7368167
Koh H et al. A radioimmunoassay of thromboxane B2 with thromboxane B2-125I-tyramide and its application to the study on the thromboxane B2 formation during platelet aggregation. 1980 Feb 1-15 Thromb. Res. pmid:7368170
Kohda N et al. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. 1999 Thromb. Res. pmid:10593428
Deckmyn H et al. Prostacyclin production by whole blood from children: impairment in the hemolytic uremic syndrome and excessive formation in chronic renal failure. 1983 Thromb. Res. pmid:6344317
Winther K et al. Platelet function and fibrinolytic activity in cervical spinal cord injured patients. 1992 Thromb. Res. pmid:1321515
Vesterqvist O et al. Development of a GC-MS method for quantitation of 2,3-dinor-TxB2 and determinations of the daily urinary excretion rates in healthy humans. 1984 Thromb. Res. pmid:6695361
Lee TK et al. Comparison of the effect of acetylsalicylic acid on platelet function in male and female patients with ischemic stroke. 1987 Thromb. Res. pmid:3629557
Tanoue K et al. A new variant of thrombasthenia with abnormally glycosylated GP IIb/IIIa. 1987 Thromb. Res. pmid:3629560
Altman R and Scazziota A Synergistic actions of paf-acether and sodium arachidonate in human platelet aggregation. 2. Unexpected results after aspirin intake. 1986 Thromb. Res. pmid:3088757
Davì G et al. Inhibition of platelet function by ticlopidine in arteriosclerosis obliterans of the lower limbs. 1985 Thromb. Res. pmid:2933846
Pattison A et al. The in vitro effect of amrinone on thromboxane B2 synthesis in human whole blood. 1986 Thromb. Res. pmid:3755259
Maguire ED and Wallis RB In vivo redirection of prostaglandin endoperoxides into 6-keto PGF1 alpha formation by thromboxane synthetase inhibitors in the rat. 1983 Thromb. Res. pmid:6689221
Weide I et al. Intravascular cysteinyl-leukotriene formation by clotting whole human blood. Evidence from clamped umbilical vein segments and thrombus specimens. 1993 Thromb. Res. pmid:8122190
Voss R et al. In vitro and ex vivo effects of aspirin in patients on a low-dose aspirin therapy. 1993 Thromb. Res. pmid:8122187
Croft KD and Beilin LJ Platelet and neutrophil function and eicosanoid release in a subject with abetalipoproteinaemia. 1993 Thromb. Res. pmid:8385810
Takasaki W et al. Enzyme immunoassay of human plasma 11-dehydrothromboxane B2. 1991 Thromb. Res. pmid:1957275
Hofmann D et al. Evidence for sustained platelet activation in patients with early postinfarction angina. 1993 Thromb. Res. pmid:8303651
Toft G et al. Intravenously and topically applied magnesium in the prevention of arterial thrombosis. 2000 Thromb. Res. pmid:10904104
Korth R et al. Unsaturated platelet-activating factor: influence on aggregation, serotonin release and thromboxane synthesis of human thrombocytes. 1986 Thromb. Res. pmid:3961742
Sinzinger H et al. Response of thromboxane B2, malondialdehyde and platelet sensitivity to 3 weeks low-dose aspirin (ASA) in healthy volunteers. 1989 Thromb. Res. pmid:2497545
Riess H et al. Thromboxane receptor blockade versus cyclooxigenase inhibition: antiplatelet effects in patients. 1986 Thromb. Res. pmid:3012819
Pirich C et al. Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients. 1999 Thromb. Res. pmid:10588465
Altman R et al. Synergistic actions of PAF-acether and sodium arachidonate in human platelet aggregation. 1. Studies in normal human platelet rich plasma. 1986 Thromb. Res. pmid:3014677
Teng CM et al. Platelet aggregation induced by equinatoxin. 1988 Thromb. Res. pmid:2906181
Selley ML et al. The effect of cholesterol oxidation products on human platelet aggregation. 1996 Thromb. Res. pmid:8885139
Yamaguchi A et al. Effect of cetiedil on platelet aggregation and thromboxane synthesis. 1985 Thromb. Res. pmid:2986312
Ding YA et al. Antiplatelet actions of 2-(4-[1-(2-chlorophenyl) piperazinyl]) methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one compound. 1995 Thromb. Res. pmid:7740521
Prosdocimi M et al. Inhibition by AD6 (8-monochloro-3-beta-diethylaminoethyl-4-methyl-7-ethoxycarbonyl methoxy coumarin) of platelet aggregation in dog stenosed coronary artery. 1985 Thromb. Res. pmid:3840290
Neiman J et al. Platelet responses to platelet-activating factor are inhibited in alcoholics undergoing alcohol withdrawal. 1989 Thromb. Res. pmid:2617478
Lukaszyk A et al. Does acute experimental pancreatitis affect blood platelet function? 1989 Thromb. Res. pmid:2524119
Swart SS et al. Functional significance of the platelet alpha2-adrenoceptor: studies in patients with myeloproliferative disorders. 1984 Thromb. Res. pmid:6326344
Ito T et al. Role of activated platelets in endotoxin-induced DIC in rats. 1990 Thromb. Res. pmid:2080492
Alessandrini P et al. Physiologic variables affecting thromboxane B2 production in human whole blood. 1985 Thromb. Res. pmid:3983893
Barbieri B et al. p-Aminobenzoic acid, but not its metabolite p-acetamidobenzoic acid, inhibits thrombin induced thromboxane formation in human platelets in a non NSAID like manner. 1997 Thromb. Res. pmid:9175234